Immunic Expands Leadership Team with Industry Veteran Jon Congleton for Strategic Growth Immunic, Inc. enhances its Board of Directors by appointing Jon Congleton, a biopharmaceutical expert, to drive innovations in neurologic disease therapies.

Immunic Expands Leadership Team with Industry Veteran Jon Congleton for Strategic Growth #United_States #New_York #Biopharmaceutical #Immunic_Inc #Jon_Congleton

Immunic, Inc. Unveils Intent for Public Offering to Boost Clinical Pipeline Immunic, Inc., a biotechnology firm, has revealed plans for a public offering. The proceeds will support clinical trials and operations for their innovative therapies.

Immunic, Inc. Unveils Intent for Public Offering to Boost Clinical Pipeline #United_States #New_York #Clinical_Trials #biotechnology #Immunic_Inc

Immunic to Showcase Innovations in Biotechnology at Upcoming Conferences This May Immunic, Inc. will present groundbreaking research at various scientific conferences. Key topics include treatments for celiac disease and multiple sclerosis, showcasing their commitment to advancing biotechnology.

Immunic to Showcase Innovations in Biotechnology at Upcoming Conferences This May #None #Immunic_Inc #IMU-838 #SIRT6

Immunic to Showcase Innovations at Upcoming Investor and Scientific Conferences in February 2025 Immunic, Inc. announces participation in multiple high-profile investor and scientific events in February, highlighting its innovative drug therapies.

Immunic to Showcase Innovations at Upcoming Investor and Scientific Conferences in February 2025 #USA #New_York #Immunic_Inc #IMU-838 #Sirtuin_6